AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS develops precision medicines to fight antimicrobial resistance.
AUROBAC THERAPEUTICS
Industry:
Biopharma Health Care Manufacturing Pharmaceutical
Founded:
2022-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.aurobac-tx.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Euro HSTS Nginx Apache 2.4 HSTS IncludeSubdomains PreLoad Ruby On Rails Token Smart App Banner Ruby On Rails Debian TurboLinks
Similar Organizations
Aga Nanotech
Aga Nanotech's mission is to overcome the increasing problem of antibiotic resistance
Alfa Farma
Alfa Farma develops drugs, diagnostic tests, and services for the healthcare sector.
Crystec Pharma
Crystec Pharma applies the latest supercritical fluid technology to improve the performance of medicines.
Peckforton Pharmaceuticals
Peckforton Pharmaceuticals is a specialty pharmaceutical company manufacturing, distributing, and selling prescription and OTC products.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Spiralps
Spiralps develops, produce and market natural products, mainly food.
Swissfillon
Swissfillon develops, manufactures, and tests pharmaceutical medicines.
Official Site Inspections
http://www.aurobac-tx.com Semrush global rank: 11.9 M Semrush visits lastest month: 143
- Host name: cluster028.hosting.ovh.net
- IP address: 51.91.236.193
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "AUROBAC THERAPEUTICS"
Our Pipeline - AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS’ R&D strategy encompasses patient- and pathogen-targeted programs designed to tackle both the causes and consequences of serious bacterial infections and AMR, including hospital-acquired and …See details»
Our Vision - AUROBAC THERAPEUTICS
As a biopharma founded in 2022 by Boehringer Ingelheim, Evotec and bioMérieux, AUROBAC THERAPEUTICS ambitions to become a leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their …See details»
AUROBAC THERAPEUTICS - LinkedIn
AUROBAC THERAPEUTICS | 1,719 followers on LinkedIn. Developing precision medicines to combat bacterial infections, AMR, and their consequences in acute care settings. | AUROBAC THERAPEUTICS is a ...See details»
Joint venture to fight Antimicrobial Resistance
Aurobac will work to shift the strategy related to antibiotic treatment regimens which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision …See details»
AUROBAC's Strategy & Pipeline Against Severe …
Jun 3, 2024 AUROBAC THERAPEUTICS (AUROBAC), a biopharmaceutical company founded by Boehringer Ingelheim, bioMérieux and Evotec, presented its strategy and pipeline for the first time today. Moreover, a new collaboration …See details»
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline …
Jun 3, 2024 AUROBAC THERAPEUTICS is also progressing a discovery and early …See details»
Aurobac Therapeutics Appoints Florence Séjourné as Chief …
Oct 4, 2022 Aurobac Therapeutics is a biotech company founded as a joint venture by …See details»
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a …
This participation in Aurobac is perfectly aligned with bioMérieux’s full commitment to sustain …See details»
Aurobac Therapeutics Company Profile 2024: Valuation, Funding ...
Aurobac Therapeutics General Information Description. Developer of precision medicine …See details»
Connect with Us - AUROBAC THERAPEUTICS
If you have an opportunity for collaboration or an interesting technology/program, or if you have …See details»
Aurobac Therapeutics presents its R&D strategy & pipeline and …
Jun 3, 2024 Aurobac Therapeutics to advance ATX101 in septic shock, and multiple …See details»
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a …
Jul 6, 2022 Aurobac will work to shift the strategy related to antibiotic treatment regimens …See details»
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline
Jun 3, 2024 AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple …See details»
AUROBAC THERAPEUTICS PRESENTS ITS R&D STRATEGY
2024.06 | AUROBAC THERAPEUTICS PRESS RELEASE 1 / 2 AUROBAC THERAPEUTICS …See details»
AUROBAC THERAPEUTICS welcomes two new independent …
Jul 24, 2023 These new appointments bring extensive US and international experience in …See details»
Aurobac Therapeutics launched to fight antimicrobial resistance
Jul 11, 2022 Aurobac Therapeutics will combine the best capabilities of the three founding …See details»
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline
Mar 6, 2024 AUROBAC THERAPEUTICS is also progressing a discovery and early …See details»
Careers - AUROBAC THERAPEUTICS
Fueled by a sense of mission and supported by an expansive worldwide community, your …See details»
POSITION: Lab Manager Type of contract Working time: Start date
Oct 14, 2024 AUROBAC THERAPEUTICS SAS 29 Avenue Tony Garnier 69007 Lyon – …See details»